Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4D | Q08499 | 2/20 | 0.34 |
| ▸ | TTK | P33981 | 1/20 | 0.32 |
| ▸ | EGFR | P00533 | 1/20 | 0.30 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL178460 | 0.80 | TTK (0.36) | PDE4DTTKIRAK4 | |
| SCHEMBL139379 | 0.78 | MAPK14 (0.37) | PDE4DTTKEGFRIRAK4 | |
| SCHEMBL104885 | 0.76 | IRAK4 (0.33) | PDE4DTTKEGFRIRAK4 | |
| SCHEMBL104841 | 0.61 | TTK (0.38) | TTKIRAK4 | |
| SCHEMBL105184 | 0.60 | ERN1 (0.41) | TTK | |
| SCHEMBL140375 | 0.57 | HPGD (0.34) | — | |
| SCHEMBL16009577 | 0.56 | TLR8 (0.36) | PDE4D | |
| SCHEMBL30224321 | 0.56 | HPGD (0.32) | IRAK4 | |
| SCHEMBL3475339 | 0.55 | CYP2C9 (0.40) | — | |
| SCHEMBL1565335 | 0.55 | DAO (0.35) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120059162-A1 | FUSED IMIDAZOLE DERIVATIVE HAVING TTK INHIBITORY ACTION | ONCOTHERAPY SCIENCE, INC. (JP) | 2012-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120059162-A1 | FUSED IMIDAZOLE DERIVATIVE HAVING TTK INHIBITORY ACTION | NR0B1, GRK7, NR5A2 | PDE4D 3509/4885TTK 6/4885EGFR 1367/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.